Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the esophagus that is unlikely to respond to existing therapy and for which no curative therapy exists~* Meets 1 of the following criteria:~  * Metastatic disease~ * Not curable with surgery or radiotherapy~* Measurable disease by MRI or CT scan~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2000/mm3~* Platelet count at least 50,000/mm3~Hepatic:~* No hepatic failure~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~Renal:~* Creatinine no greater than 2.5 mg/ml~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No chronic or congestive heart failure~* No uncontrolled hypertension~* No other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No serious lung disease, such as severe chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No medical illness, psychiatric illness, or non-malignant systemic disease that would preclude study treatment~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~Endocrine therapy:~* Concurrent steroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy (except in patients with multiple tumors who have received radiotherapy to some of their tumors) and recovered~Surgery:~* Recovered from prior surgery~Other:~* No prior antineoplaston therapy~* Prior cytodifferentiating agents allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).